Use of placental therapy in the correction of functional impairments in women: investigations and clinical practice

Combination therapy for female functional disorders, which is aimed at both correcting pathological conditions and improving the quality of life, is the most important task of modern gynecology. Hormone therapy that is effective in many of these disorders is often ineffective and/or unacceptable for several reasons, and there is a need to search for alternative methods and approaches. One of these approaches is the use of organ preparations as a human placental extract. One placental drug Melsmon manufactured by Melsmon Pharmaceutical Co., Ltd., Japan, has been registered in Russia for gynecological indications. The goal of this paper is to generalize the experience in conducting clinical trials and using placental drugs in medical practice and to outline the prospects for their further trials and application. Melsmon that has proven to be effective and safe for menopausal syndrome, is being tested and used in the combination correction of diseases, such as genitourinary syndrome of menopause, premature ovarian failure, and in the maintenance therapy of gynecological cancer patients to increase the implantation susceptibility of the endometrium in infertility.

menopausal syndrome, clinical trials, placental therapy